Researchers reported "high efficacy and an excellent safety profile" for direct-acting antiviral (DAA) combinations with daclatasvir (DCV) among transplanted patients with hepatitis C virus (HCV) infection.
Data from a retrospective cohort study presented at The Liver Meeting® 2016 has shown that hepatitis C virus (HCV)-infected patients with advanced chronic kidney disease (CKD) "remains a challenging population to treat," with <10% receiving treatment in the early direct-acting antivirals (DAA) era.
A fixed-dose combination of pangenotypic direct-acting antivirals was "highly effective" in treatment-naïve patients with hepatitis C virus (HCV) genotypes (GT) 1, 2, and 3
Treatment with single tablet sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks "is a highly effective salvage therapy" for patients who did not previously achieve sustained virologic response (SVR) following treatment with non-NS5A inhibitor-containing direct-acting antivirals (DAAs), results from the POLARIS-4 study presented at The Liver Meeting® 2016 have shown.
3-DAA ± ribavirin achieved high 12-week sustained virologic response rates in Brazilian patients with GT1 hepatitis C virus (HCV) with bridging fibrosis or compensated cirrhosis.
No clinically significant changes in heart rate or cardiac adverse events were observed in patients with hepatitis C virus (HCV) infection on beta blockers receiving sofosbuvir (SOF)-based regimens, results of a study presented at The Liver Meeting® have found.
The all-oral, ribavirin-free glecaprevir/pibrentasvir regimen achieved high SVR12 rates in non-cirrhotic patients with hepatitis C virus (HCV) genotype (GT) 4, 5, and 6 infection, the phase 3 ENDURANCE-4 study concluded at The Liver Meeting® 2016.
An investigational oral 40mg immediate-release rifaximin formulation reduces hospitalization and mortality in patients with cirrhosis with well-controlled ascites.
IFN-free DAA regimens are safe and effective for elderly patients with hepatitis C virus (HCV)-related cirrhosis or severe fibrosis.
Long-term use of proton pump inhibitors (PPIs) reduces bleeding-related mortality in patients with cirrhosis and variceal bleeding, a prospective study reported at The Liver Meeting® 2016.
Ledipasvir/Sofosbuvir with or without ribavirin is associated with comparable sustained virologic response (SVR) rates for African American patients and non-African Americans who have HIV/HCV co-infection, but cirrhosis was associated with significantly poorer rates.
No resistance to tenofovir alafenamide (TAF) was detected through week 48 in adults with chronic hepatitis B virus (HBV), regardless of whether they were treatment-naïve or -experienced, results of two phase 3 studies presented at The Liver Meeting® 2016 have shown.
Use of telbivudine and tenofovir in middle-to-late pregnancy was equally effective in reducing mother-to-infant chronic hepatitis B virus (HBV) infection vertical transmission, a real world study in China reported at The Liver Meeting® 2016
Ledipasvir and sofosbuvir yielded 100% SVR in patients with thalassemia major, a genetic disease, who become infected with hepatitis C virus genotypes 1 and 4.
In patients with chronic hepatitis C virus (HCV) infection and intermediate stage hepatocellular carcinoma (HCC) who receive transarterial chemoembolization (TACE), the SVR achieved with pegylated-interferon (pegIFN/ribavirin (RBV) treatment markedly improved survival and reduced tumor recurrence, a study presented at The Liver Meeting 2016® concluded.
Compared with carvedilol alone, adding simvastatin to carvedilol did not improve hemodynamic efficacy or reduce incidence of first bleed in patients with cirrhosis with varices without a prior bleed, preliminary results of an open-label randomized controlled trial reported at The Liver Meeting® 2016
Patient-reported outcome scores improve significantly for HIV-HCV co-infected patients undergoing sofosbuvir and velpatasvir therapy.
Combined dapagliflozin (DAPA) and free omega-3 fatty acid carboxylic acids (OM-3 CA) significantly reduce liver fat among patients with type 2 diabetes and non-alcoholic liver disease.
Patients with HCV GT1 with decompensated cirrhosis treated in the real world with ledipasvir/sofosbuvir plus ribavirin achieved high cure rates and comparable MELD improvement to patients in clinical trials.
Coffee drinkers significantly decrease their risk of nonalcoholic fatty liver disease (NAFLD), and regular drinking also decreases risk of liver fibrosis, according to results of a systematic review and meta-analysis presented at The Liver Meeting® 2016.
A combination of investigative direct-acting antivirals and simeprevir (SMV) is well tolerated in healthy volunteers.
Omega-3 fatty acids are associated with a significant reduction in liver fat in patients with hepatic steatosis, a systematic review and meta-analysis presented at The Liver Meeting® 2016 has found.
Long-term follow-up data show that sustained virologic response (SVR) at 12 weeks achieved with daclatasvir (DCV)-based regimens are durable in patients with chronic hepatitic C virus (HCV) infection, study authors reported at The Liver Meeting® 2016.
Ledipasvir/sofosbuvir therapy for patients with HIV/HCV co-infection is comparably effective in real-world clinical settings and clinical trials.
At The Liver Meeting® 2016, scientists reported that treatment with ledipasvir/sofosbuvir (LDV/SOF) for 6 weeks was well tolerated and highly effective in patients with acute hepatitis C virus (HCV) GT 1 infection.
Consistent concomitant use of proton pump inhibitors (PPIs) with elbasvir/grazoprevir (EBR/GZR) had no clinically significant effect on 12-week sustained viral response (SVR12) rates in patients with hepatitis C virus (HCV) genotype (GT)1 or GT4 infection with and without cirrhosis, according to research presented at The Liver Meeting® 2016